Mitotane-13C6

Mitotane-13C6 is the 13C labeled Mitotane[1]. Mitotane (2,4′-DDD), an isomer of DDD and derivative of dichlorodiphenyltrichloroethane (DDT), is an antineoplastic agent, can be used to research adrenocortical carcinoma. Mitotane exert its adrenocorticolytic effect at least in part through lipotoxicity induced by intracellular free cholesterol (FC) accumulation. Mitotane can have direct pituitary effects on corticotroph cells. Mitotane can induce CYP3A4 gene expression via steroid and xenobiotic receptor (SXR) activation, and has agent-agent interactions[2][3][4][5].

Product Specifications

CAS Number

[1261396-21-7]

Product Name Alternative

2,4′-DDD-13C6; o, p'-DDD-13C6

UNSPSC

12352005

Target

Apoptosis

Type

Isotope-Labeled Compounds

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/mitotane-13c6.html

Purity

98.62

Solubility

10 mM in DMSO

Smiles

ClC(Cl)C([13C]1=[13CH][13CH]=[13C]([13CH]=[13CH]1)Cl)C2=C(C=CC=C2)Cl

Molecular Formula

C8 13C6H10Cl4

Molecular Weight

326.00

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]Takeshita A, Igarashi-Migitaka J, Koibuchi N, Mitotane induces CYP3A4 expression via activation of the steroid and xenobiotic receptor. J Endocrinol. 2013 Feb 15;216 (3) :297-305.|[3]Doghman M, et al. Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma. Mol Cell Endocrinol. 2013 Dec 5;381 (1-2) :66-9.|[4]Zatelli MC, et al. Therapeutic concentrations of mitotane (o, p'-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model. Endocrinology. 2010 Jun;151 (6) :2453-61.|[5]Warde KM, et al. Mitotane Targets Lipid Droplets to Induce Lipolysis in Adrenocortical Carcinoma. Endocrinology. 2022 Sep 1;163 (9) :bqac102.